Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
Authors
Keywords
-
Journal
Frontiers in Cardiovascular Medicine
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-10-28
DOI
10.3389/fcvm.2022.1028355
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
- (2022) Lawrence A. Leiter et al. DIABETES OBESITY & METABOLISM
- Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study
- (2022) Philippe van de Borne et al. ACTA CARDIOLOGICA
- Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis
- (2022) Yingfeng Lin et al. BMJ Open
- Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism
- (2022) Xuan Xiao et al. Frontiers in Cardiovascular Medicine
- Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
- (2022) Marisa R. Morrow et al. Cell Metabolism
- Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know
- (2022) Johnathon Seth Parham et al. Current Atherosclerosis Reports
- New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
- (2022) Iveta Merćep et al. Pharmaceuticals
- Role of Bempedoic Acid in Clinical Practice
- (2021) Christie M. Ballantyne et al. CARDIOVASCULAR DRUGS AND THERAPY
- Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia
- (2021) Arrigo F.G. Cicero et al. Expert Opinion on Drug Metabolism & Toxicology
- Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
- (2021) Antonio J. Vallejo-Vaz et al. LANCET
- The Aging Muscle in Experimental Bed Rest: A Systematic Review and Meta-Analysis
- (2021) Filippo Giorgio Di Girolamo et al. Frontiers in Nutrition
- Pharmacokinetics of bempedoic acid in patients with renal impairment
- (2021) Benny M. Amore et al. CTS-Clinical and Translational Science
- LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments
- (2021) Christos V. Rizos et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy
- (2021) Pierandrea Vinci et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia
- (2021) Maurizio Averna et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis
- (2021) Sanne G.S. Verberk et al. TRENDS IN MOLECULAR MEDICINE
- Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies
- (2020) Arrigo F. G. Cicero et al. DRUG SAFETY
- Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis
- (2020) Xing Wang et al. Cardiovascular Diabetology
- Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
- (2020) Maciej Banach et al. JAMA Cardiology
- Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance
- (2020) Stephen J Nicholls et al. AMERICAN HEART JOURNAL
- Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
- (2020) Harold E. Bays et al. Journal of Clinical Lipidology
- Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial
- (2020) John Rubino et al. ATHEROSCLEROSIS
- Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real‐life setting: the PROSISA Study
- (2020) M. Casula et al. JOURNAL OF INTERNAL MEDICINE
- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
- (2019) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mendelian Randomization Study of ACLY and Cardiovascular Disease
- (2019) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjects
- (2019) Tomohisa Nakada et al. Drug Metabolism and Pharmacokinetics
- Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized, placebo-controlled trial
- (2019) Narendra D. Lalwani et al. Journal of Clinical Lipidology
- Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
- (2019) Ulrich Laufs et al. Journal of the American Heart Association
- Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
- (2019) Christie M Ballantyne et al. European Journal of Preventive Cardiology
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. ATHEROSCLEROSIS
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
- (2019) Anne C. Goldberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes?
- (2018) M. Ruscica et al. ANNALS OF MEDICINE
- Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient (LDLR+/−andLDLR−/−) Yucatan Miniature PigsHighlights
- (2018) Amy C. Burke et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
- (2018) Christie M. Ballantyne et al. ATHEROSCLEROSIS
- Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
- (2018) Paul M Ridker et al. LANCET
- Reinitiation of Statin Therapy After Discontinuation: A Meta-analysis
- (2018) Richard Ofori-Asenso et al. MAYO CLINIC PROCEEDINGS
- Contraction and nutrition interaction promotes anabolism in cachectic muscle
- (2018) Filippo Giorgio Di Girolamo et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Bempedoic acid
- (2018) Amy C. Burke et al. CURRENT OPINION IN LIPIDOLOGY
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Higher protein intake is associated with improved muscle strength in elite senior athletes
- (2017) Filippo Giorgio Di Girolamo et al. NUTRITION
- Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance
- (2016) Paul D. Thompson et al. Journal of Clinical Lipidology
- Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
- (2016) Stephen L. Pinkosky et al. Nature Communications
- Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance
- (2015) Paul D. Thompson et al. Journal of Clinical Lipidology
- Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus
- (2014) Maria J. Gutierrez et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Polymorphisms, de novo lipogenesis, and plasma triglyceride response following fish oil supplementation
- (2013) Annie Bouchard-Mercier et al. JOURNAL OF LIPID RESEARCH
- ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK
- (2013) Sergey Filippov et al. JOURNAL OF LIPID RESEARCH
- AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism
- (2012) Stephen L. Pinkosky et al. JOURNAL OF LIPID RESEARCH
- The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues
- (2012) Lawrence J. Laslett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Statins on Creatine Kinase Levels Before and After a Marathon Run
- (2011) Beth A. Parker et al. AMERICAN JOURNAL OF CARDIOLOGY
- Renal Secretion of Uric Acid by Organic Anion Transporter 2 (OAT2/SLC22A7) in Human
- (2010) Masanobu Sato et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice
- (2008) Catherine Postic et al. JOURNAL OF CLINICAL INVESTIGATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started